*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*                                                                     *x*
*x*            Copyright (C) 1990 University of Pennsylvania            *x*
*x*                                                                     *x*
*x*    The data in this file are part of a preliminary version of the   *x*
*x*    Penn Treebank Corpus.  Any research using this corpus or based   *x*
*x*    on it should acknowledge that fact, as well as the preliminary   *x*
*x*    nature of the corpus.                                            *x*
*x*                                                                     *x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*



======================================

[ Lyphomed/NNP Inc./NNP ]
plans/VBZ to/TO distribute/VB for/IN 
[ free/JJ ]
to/TO 
[ indigent/JJ patients/NNS ]

[ an/DT aerosol/NN drug/NN ]

[ that/WDT ]
can/MD prevent/VB 
[ a/DT type/NN ]
of/IN 
[ pneumonia/NN ]

[ that/WDT ]
kills/VBZ as/RB many/JJ as/IN 
[ 80/CD %/NN ]
of/IN 
[ all/DT AIDS/NNP patients/NNS ]
./. 

======================================

[ The/DT drug/NN manufacturer/NN ]
has/VBZ been/VBN considering/VBG 
[ the/DT idea/NN ]
of/IN 
[ free/JJ distribution/NN ]
for/IN 
[ the/DT last/JJ couple/NN ]
of/IN 
[ months/NNS ]
,/, but/CC decided/VBD to/TO give/VB 
[ aerosol/NN pentamidine/NN ]
at/IN 
[ no/DT charge/NN ]
only/RB to/TO 
[ patients/NNS ]

[ who/WP ]
ca/MD n't/RB afford/VB 
[ it/PRP ]
,/, said/VBD 
[ John/NNP N./NNP Kapoor/NNP ]
,/, 
[ chairman/NN ]
of/IN 
[ the/DT Rosemont/NNP ]
,/, 
[ Ill./NNP ]
,/, 
[ company/NN ]
./. 

======================================

[ Dispersals/NNS ]
should/MD begin/VB within/IN 
[ a/DT week/NN ]
,/, 
[ Mr./NNP Kapoor/NNP ]
said/VBD ./. 

[ It/PRP ]

[ was/VBD n't/RB ]
clear/JJ ,/, however/RB ,/, how/WRB 
[ the/DT drug/NN ]
will/MD be/VB distributed/VBN or/CC how/WRB 
[ many/JJ patients/NNS ]

[ it/PRP ]
would/MD effect/VB ./. 

======================================

[ The/DT target/NN group/NN ]
will/MD include/VB 
[ patients/NNS whose/WP$ insurance/NN policies/NNS ]
do/VBP n't/RB cover/VB 
[ the/DT cost/NN ]
of/IN 
[ the/DT drug/NN ]
,/, 
[ Mr./NNP Kapoor/NNP ]
said/VBD ./. 

======================================

[ The/DT move/NN ]
follows/VBZ 
[ months/NNS ]
of/IN 
[ criticism/NN ]
by/IN 
[ AIDS/NNP activists/NNS ]

[ who/WP ]
accused/VBD 
[ the/DT company/NN ]
of/IN profiteering/NN ./. 

Typically/RB ,/, 
[ aerosol/NN pentamidine/NN costs/VBZ ]
about/IN 
[ $/$ 100/CD ]
for/IN 
[ a/DT 300/CD milligram/NN dose/NN ]
taken/VBN once/IN 
[ a/DT month/NN ]
./. 

======================================

[ The/DT drug/NN ]
,/, along/IN with/IN 
[ Burroughs/NNP Wellcome/NNP Co./NNP 's/POS AZT/NNP ]
,/, is/VBZ credited/VBN with/IN helping/VBG prolong/VB 
[ the/DT lives/NNS ]
of/IN 
[ people/NNS ]
with/IN 
[ AIDS/NNP ]
./. 

======================================

[ Last/JJ summer/NN ]
,/, 
[ the/DT Food/NNP ]
and/CC 
[ Drug/NNP Administration/NNP ]
granted/VBD 
[ approval/NN ]
for/IN 
[ aerosol/NN pentamidine/NN ]
,/, 
[ which/WDT staves/VBZ ]
off/RB 
[ both/DT ]

[ first/JJ attacks/NNS ]
and/CC 
[ recurrences/NNS ]
of/IN 
[ pneumocystis/NN carinii/NN pneumonia/NN ]
,/, 
[ a/DT deadly/JJ AIDS-related/JJ form/NN ]
of/IN 
[ the/DT illness/NN ]
./. 

======================================

[ Lyphomed/NNP ]
currently/RB is/VBZ 
[ the/DT sole/JJ supplier/NN ]
of/IN 
[ the/DT drug/NN ]
./. 

As/IN 
[ a/DT so-called/JJ orphan/NN drug/NN ]
,/, or/CC 
[ one/NN ]
aimed/VBN at/IN 
[ a/DT small/JJ market/NN ]
,/, 
[ aerosol/NN pentamidine/NN ]
is/VBZ protected/VBN by/IN 
[ a/DT seven-year/JJ exclusive/JJ patent/NN ]
./. 

[ Lyphomed/NNP 's/POS closest/JJS rival/NN ]
is/VBZ 
[ a/DT British/JJ company/NN ]
,/, 
[ Fisons/NNP PLC/NNP ]
,/, 
[ which/WDT ]
has/VBZ submitted/VBN 
[ its/PRP$ own/JJ research/NN ]
to/TO 
[ the/DT FDA/NNP ]
,/, but/CC 
[ has/VBZ n't/RB ]
yet/RB gotten/VBN 
[ approval/NN ]
./. 

======================================

[ Candidates/NNS ]
for/IN 
[ the/DT drug/NN ]
are/VBP 
[ AIDS/NNP patients/NNS whose/WP$ count/NN ]
on/IN 
[ T-helper/NN lymphocytes/NNS ]
,/, 
[ cells/NNS ]
vital/JJ to/TO 
[ the/DT immune/JJ system/NN ]
,/, falls/VBZ below/IN 
[ 200/CD ]
per/IN 
[ cubic/JJ millimeter/NN ]
of/IN 
[ blood/NN ]
./. 

[ Such/JJ a/DT level/NN ]
places/VBZ 
[ them/PRP ]
in/IN 
[ the/DT highest/JJS danger/NN ]
of/IN 
[ developing/VBG pneumonia/NN ]
./. 

======================================

[ Estimates/NNS ]
vary/VBP widely/RB as/IN to/TO how/WRB 
[ many/JJ AIDS/NNP patients/NNS ]
are/VBP 
[ candidates/NNS ]
for/IN 
[ the/DT drug/NN ]
./. 

But/CC 
[ the/DT aerosal/NN ]
is/VBZ also/RB used/VBN by/IN 
[ people/NNS ]

[ who/WP ]
have/VBP contracted/VBN 
[ the/DT virus/NN ]

[ that/WDT ]
causes/VBZ 
[ AIDS/NNP ]
,/, but/CC 
[ who/WP ]
have/VBP n't/RB developed/VBN 
[ the/DT disease/NN ]
./. 

======================================

[ Separately/RB ]
,/, 
[ Fujisawa/NNP Pharmaceutical/NNP Co./NNP ]
said/VBD that/IN Lyphomed/NNP 
[ shareholders/NNS ]
had/VBD tendered/VBN 
[ 99.2/CD %/NN ]
of/IN 
[ the/DT company/NN 's/POS outstanding/JJ shares/NNS ]
under/IN 
[ its/PRP$ $/$ 31.87-a-share/JJ buy-out/NN proposal/NN ]
./. 

[ The/DT offer/NN ]
values/VBZ 
[ the/DT total/JJ company/NN ]
at/IN 
[ $/$ 956.7/CD million/CD ]
./. 

======================================

[ Fujisawa/NNP ]
said/VBD 
[ it/PRP ]
received/VBD 
[ 18.4/CD million/CD shares/NNS ]
under/IN 
[ the/DT offer/NN ]
,/, 
[ which/WDT ]
expired/VBD 
[ Tuesday/NNP ]
./. 
